Navigation Links
Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
Date:11/14/2007

der development at Xenomics."

About Xenomics, Inc.

Xenomics is a molecular diagnostics company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a European patent for the Company's prenatal testing applications, and numerous pending patent applications. For more investor-specific information, including daily and historical Company stock quote data, recent news releases and an Investor Fact Sheet, please visit http://www.xenomics.com. Xenomics is also listed on the Frankfurt Stock Exchange under the symbol XE7.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics' Form 10-KSB as filed with the Securities and Exchange Commission on May 16, 2006 and its other periodic reports, actual results cou
'/>"/>

SOURCE Xenomics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...v. 20 Medco Health Solut...a transformation in American healthcare through an... delivering higher quality clinical care and funda... medicine smarter for the benefit of patients and ...w the elements in its strategy enable "Smarter Med...
(Date:11/20/2009)..., Nov. 20 ,, Reportlinker.com ...ilable in its catalogue. ,, India Medical Equi... http://www.reportlinker.com/p0164658/India-Medi...5.html#utm_source=prnewswire&utm_medium=pr&..., India Medical Equipment Market Analysis and For...
(Date:11/20/2009)...ov. 20 Biotel Inc. (OTC ...rst quarter ended September 30, 2009 with net earn...evenues of $3,263,000. This compares to net earni...venues of $3,168,000 for the first quarter of last...ts, Biotel President and CEO Steve Springrose said...
Breaking Medicine Technology:Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 2Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 3Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 4Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 2Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 3Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 4Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 6Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 7Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 8Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 9Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 10Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 11Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 12Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 13Biotel Announced Profitable First Quarter Ended September 30, 2009 2Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 1Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 2Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 4Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 1Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 4Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 6Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 7Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 1Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 3Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 4Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 5
...DIEGO, April 15 Cardium Therapeutics,(Amex: CXM ...nced today that,positive findings from a preclinic... of early rapid hyperthermia (cooling) for the pot...eart attack), has been published,online by BioMed ... April,10, 2008)., (Photo: http://www.newscom.co...
...w Approach to Targeting the Tumor Microenvironment...c. (Nasdaq: HALO ), a biopharmaceutical company d...he extracellular matrix, today,announced new pre-c...er,models at the American Association for Cancer R...ng its Pegylated-rHuPH20 enzyme (PEGrHuPH20) as a,...
Other Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 2Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 3Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference 4
(Date:11/21/2009)... Linwood Group ask whether there is a sec...red? , London, UK (PRWEB)...th up to one in three of the adult UK population d...ing alcohol-related liver disease*, it is hardly a...habilitation programmes and residential centres fo...
(Date:11/20/2009)...CETON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRYS...cial Meeting of Shareholders will be held on Monda...s to consider approval of two special resolutions....thorize the sale of all or substantially all of th...ovided for in the asset purchase agreement dated N...
(Date:11/20/2009)...WASHINGTON, Nov. 20 The...d the Senate to make essential changes its health ...on abortion funding and conscience protection on a...nts and include strong provisions for adequate aff...alth care bill an "enormous disappointment" that c...
(Date:11/20/2009)... Senators and Congressmen in Competitive ... Health Care Vote , Washi...d congressmen running for re-election next year in...Charlie Cook, may come to regret voting for House ...ording to a breaking Zogby International/ O’...
(Date:11/20/2009)...GO, Nov. 20 The America...od and Drug Administration (FDA) to establish appr...als. ,, Citing concern about the safety of whi...t the benefit of professional consultation or exam...e application of chemically based tooth whitening ...
Breaking Medicine News(10 mins):Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2
...Court today has issued a notice to the Centre aski...ion to implement 27 per cent reservation was taken...inuing, the Supreme Court today decided to examine...ns. Questioning the basis on which governmen...
...lywood has a fine tradition of remaking Hollywood ...comedy, Munnabhai MBBS, is set to be remade in the...anjay Dutt, a flick about a gangster who pretends ... Nair said Chris Tucker, the Hollywood action s...
...ed at birth. Even the sex drive, researchers say. ...y may not work to cure 'sex addicts'// , for the a... clue, for people who are more driven than others ... The scientists say that differences in the gene ,...
...published contradicts the previous research that s...cer. The latest Study shows that a high fat intak...opment of non-melanoma skin cancer. Robert Gr...tudied 652 people who had been diagnosed with skin...
...at the University of Surrey in Guildford are plann...relationship between men and women//. This study i...ological and emotional effects of the cancer on UK...l lives of couples. The researchers have said that...
... health agency says, as smoking, eating poor diets...uman health into trouble//. ...sumption of fish, fruit and vegetables leads to mo...ronment (RIVM), reported that unhealthy dietary ha...
Other Medicine News:Health News:Supreme Court Verdict Gives Hope to Striking Medicos 2Health News:Unhealthy Diet Reduces Life Expectancy 2
Ocular Three Mirror 10 mm Gonio
Ocular Magna View Gonio
Ocular Koeppe Diagnostic
Mcintyre Cannula
Medicine Products: